Cargando…

Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?

BACKGROUND: Chronic osteomyelitis is a challenge for orthopedic surgeons. Most patients with osteomyelitis receive two-stage management according to Cierny-Mader. The first stage includes radical debridement and insertion of an antibiotic-impregnated cement spacer (ACS) (beads, rods, nails, or block...

Descripción completa

Detalles Bibliográficos
Autores principales: Bor, Noam, Dujovny, Eytan, Rinat, Barak, Rozen, Nimrod, Rubin, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740499/
https://www.ncbi.nlm.nih.gov/pubmed/34991574
http://dx.doi.org/10.1186/s12891-021-04979-y
_version_ 1784629326878081024
author Bor, Noam
Dujovny, Eytan
Rinat, Barak
Rozen, Nimrod
Rubin, Guy
author_facet Bor, Noam
Dujovny, Eytan
Rinat, Barak
Rozen, Nimrod
Rubin, Guy
author_sort Bor, Noam
collection PubMed
description BACKGROUND: Chronic osteomyelitis is a challenge for orthopedic surgeons. Most patients with osteomyelitis receive two-stage management according to Cierny-Mader. The first stage includes radical debridement and insertion of an antibiotic-impregnated cement spacer (ACS) (beads, rods, nails, or blocks) into the bone defect. The second stage is performed 6–8 weeks later, when the spacer is removed and a cancellous autograft is placed within the bone defect. The possibility of ACS as definitive management for osteomyelitis, avoiding the second stage, is presented. METHODS: Sixteen patients with osteomyelitis received radical debridement and insertion of an ACS in all forms into the bone defect as a definitive management. In 8 patients, the tibia was infected, 4 had femur infection, 2 humerus, 1 fibula, and 1 ankle. The mean age at the time of the first stage of reconstruction was 49 years (range, 13–71 years). According to the Cierny-Mader classification, 1 patient was C-M IA, another was IB, 7 IIIA, 6 IIIB, and 1 was 4A. All B hosts had systemic illnesses. The mean follow-up period was 6 years (1.5–16 years). RESULTS: No patient exhibited radiographic evidence of excessive bone loss. Signs of recurrence of osteomyelitis were not noted in any of the patients, and no fractures had occurred by the last follow-up. CONCLUSION: Our study suggests that a proportion of patients with planned retention of ACS appear to function well without requiring further surgical intervention, especially in elderly or vulnerable patients.
format Online
Article
Text
id pubmed-8740499
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87404992022-01-07 Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary? Bor, Noam Dujovny, Eytan Rinat, Barak Rozen, Nimrod Rubin, Guy BMC Musculoskelet Disord Research BACKGROUND: Chronic osteomyelitis is a challenge for orthopedic surgeons. Most patients with osteomyelitis receive two-stage management according to Cierny-Mader. The first stage includes radical debridement and insertion of an antibiotic-impregnated cement spacer (ACS) (beads, rods, nails, or blocks) into the bone defect. The second stage is performed 6–8 weeks later, when the spacer is removed and a cancellous autograft is placed within the bone defect. The possibility of ACS as definitive management for osteomyelitis, avoiding the second stage, is presented. METHODS: Sixteen patients with osteomyelitis received radical debridement and insertion of an ACS in all forms into the bone defect as a definitive management. In 8 patients, the tibia was infected, 4 had femur infection, 2 humerus, 1 fibula, and 1 ankle. The mean age at the time of the first stage of reconstruction was 49 years (range, 13–71 years). According to the Cierny-Mader classification, 1 patient was C-M IA, another was IB, 7 IIIA, 6 IIIB, and 1 was 4A. All B hosts had systemic illnesses. The mean follow-up period was 6 years (1.5–16 years). RESULTS: No patient exhibited radiographic evidence of excessive bone loss. Signs of recurrence of osteomyelitis were not noted in any of the patients, and no fractures had occurred by the last follow-up. CONCLUSION: Our study suggests that a proportion of patients with planned retention of ACS appear to function well without requiring further surgical intervention, especially in elderly or vulnerable patients. BioMed Central 2022-01-06 /pmc/articles/PMC8740499/ /pubmed/34991574 http://dx.doi.org/10.1186/s12891-021-04979-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bor, Noam
Dujovny, Eytan
Rinat, Barak
Rozen, Nimrod
Rubin, Guy
Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?
title Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?
title_full Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?
title_fullStr Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?
title_full_unstemmed Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?
title_short Treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (PMMA) – the Cierny approach: is the second stage necessary?
title_sort treatment of chronic osteomyelitis with antibiotic-impregnated polymethyl methacrylate (pmma) – the cierny approach: is the second stage necessary?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740499/
https://www.ncbi.nlm.nih.gov/pubmed/34991574
http://dx.doi.org/10.1186/s12891-021-04979-y
work_keys_str_mv AT bornoam treatmentofchronicosteomyelitiswithantibioticimpregnatedpolymethylmethacrylatepmmatheciernyapproachisthesecondstagenecessary
AT dujovnyeytan treatmentofchronicosteomyelitiswithantibioticimpregnatedpolymethylmethacrylatepmmatheciernyapproachisthesecondstagenecessary
AT rinatbarak treatmentofchronicosteomyelitiswithantibioticimpregnatedpolymethylmethacrylatepmmatheciernyapproachisthesecondstagenecessary
AT rozennimrod treatmentofchronicosteomyelitiswithantibioticimpregnatedpolymethylmethacrylatepmmatheciernyapproachisthesecondstagenecessary
AT rubinguy treatmentofchronicosteomyelitiswithantibioticimpregnatedpolymethylmethacrylatepmmatheciernyapproachisthesecondstagenecessary